Filing Flows › Ideaya Biosciences (IDYA) › Q3 2026
Ideaya Biosciences (IDYA) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
Ideaya Biosciences (IDYA) reported revenue of $10.2M for the third quarter 2026 (Q3 2026), -95% from a year earlier and +16% from the quarter before.
Ideaya Biosciences, Q3 2026: revenue $10.2M (-95% year over year), net loss $126M, operating cash flow −$93.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.2M | +16% | -95% |
| Operating profit | −$138M | — | -227% |
| Net earnings | −$126M | — | -205% |
| Operating cash flow | −$93.5M | — | -166% |
What changed
Revenue was $10.2M in Q3 2026, down 95% year over year and up 16% from the previous quarter.
Operating costs exceeded revenue by $137.6M, an operating margin of -1343.8%. Total costs grew 49% against a revenue fall of 95%. The fastest-growing cost line was General & admin (+60%). The quarter ended with a net loss of $125.7M, wider than the previous quarter's $112.5M loss.
Operating cash flow was −$93.5M. Non-cash charges added back $614K of depreciation and amortization and $17.7M of share-based compensation. Working capital and other items added $13.9M. Capital expenditures of $273K exceeded it, leaving free cash flow of −$93.8M.
Questions
What was Ideaya Biosciences' revenue in the third quarter 2026?
Ideaya Biosciences (IDYA) reported revenue of $10.2M for the third quarter 2026 (Q3 2026), -95% from a year earlier and +16% from the quarter before.
Source: Ideaya Biosciences 10-Q on SEC EDGAR.